C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma TrialBenzinga • 04/08/22
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 DegraderGlobeNewsWire • 04/08/22
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue SarcomaGlobeNewsWire • 03/09/22
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 03/08/22
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/24/22
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation PortfolioGlobeNewsWire • 01/10/22
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/22
C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 11/22/21
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/10/21
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/11/21
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple MyelomaGlobeNewsWire • 08/11/21
C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 06/21/21
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic MalignanciesGlobeNewsWire • 06/14/21
C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein DegradationGlobeNewsWire • 06/07/21
C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial ResultsGlobeNewsWire • 05/13/21